http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
윤한수(Hansoo Yun),이현소(Hyunso Lee),최성진(Sungjin Chol),이승희(Seunghee Lee),이창선(Changsun Lee),이강식(Kangsik Lee) 한국추진공학회 2022 한국추진공학회 학술대회논문집 Vol.2022 No.5
국내에서는 나로호, 누리호 등 중형발사체의 개발이 이루어졌으나, 소형발사체는 개발이 시작되는 단계이다. 소형발사체에 적용되는 에비오닉스 시스템의 기능 요구사항은 중형발사체 시스템과 동일하나, 소형발사체의 특성에 따라 중량 절감 및 저비용화 개발이 필수적인 요소이다. 이러한 소형발사체 에비오닉스 시스템의 요구사항을 충족하기 위해 공통 플랫폼 기반 모듈화 설계 및 조합을 통해 장비를 구성함에 따라 소형, 경량화가 가능하며, 다양한 발사체 환경에 적용하기 위해 네트워크 기반의 시스템 설계를 적용하여 유연성을 확보하도록 설계하였다. 또한 발사체의 안전을 담당하는 비행 안전 시스템은 자율 비행 안전 시스템을 적용하여 지상시스템 간소화 및 운영인원의 감축을 통해 운영비용을 절감할 수 있도록 설계함으로서, 소형발사체의 경제적 발사 서비스가 가능한 에비오닉스 시스템을 설계하였다. In Korea, the development of medium-lift launch vehicle was carried out the development of Naro and Nuri, But the development of small launch vehicle is now in the beginning stage. The avionics system of small launch vehicle is not much different from the functions required by medium-lift launch vehicle, but the economical launch service of small launch vehicle requires development by significantly reducing the cost and weight of avionics system compared to medium-lift launch vehicle. To apply the requirement of the avionics system of small launch vehicle, the hardware is designed to develop equipment through a combination of small and lightweight functional modules and to provide flexibility through network-based system design for application to multiple projectiles. The flight safety system, which is responsible for the safety of launch vehicle, is designed to reduce operating costs by reducing ground system and operating personnel by applying an autonomous flight safety system, and thus designed and avionics system capable of economic launch of small launch vehicle.
Lee, Gwangsoo,Na, Hee-Jun,Namkoong, Seung,Jeong Kwon, Ho,Han, Sanghwa,Ha, Kwon-Soo,Kwon, Young-Guen,Lee, Hansoo,Kim, Young-Myeong Elsevier 2006 european journal of pharmacology Vol.551 No.1
<P><B>Abstract</B></P><P>We here investigated the functional effect of 4-<I>O</I>-methylgallic acid (4-OMGA), a major metabolite of gallic acid abundant in red wine, on vascular inflammation and its action mechanism. 4-OMGA inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with tumor necrosis factor-α (TNF-α), resulting in the suppression of leukocyte adhesion to HUVECs. In addition, 4-OMGA inhibited the promoter activities of ICAM-1 and VCAM-1 and the activity of nuclear factor-κB (NF-κB) without affecting cytosolic IκB kinase (IKK) activation, inhibitor of κB (IκB) phosphorylation and degradation, and nuclear translocation of NF-κB. This compound did not alter nitric oxide (NO) generation, but inhibited reactive oxygen species (ROS) production in TNF-α-stimulated HUVECs, suggesting that NO and ROS are not involved in 4-OMGA-mediated inhibition of NF-κB activity. Moreover, 4-OMGA directly blocked the binding activity of NF-κB to its consensus DNA oligonucleotide, when pre-incubated with the nuclear extract from TNF-α-stimulated HUVECs, but not with the oligonucleotide alone. This inhibition was completely abolished by the addition of dithiothreitol. 4-OMGA exhibits an anti-inflammatory property by interfering with the formation of the NF-κB-DNA complex in the nuclei through direct and redox-sensitive interactions and may play an important role in the prevention of inflammatory responses such as the atherosclerotic process.</P>
Current Status of Pyroprocessing Development at KAERI
Lee, Hansoo,Park, Geun-IL,Lee, Jae-Won,Kang, Kweon-Ho,Hur, Jin-Mok,Kim, Jeong-Guk,Paek, Seungwoo,Kim, In-Tae,Cho, IL-Je Hindawi Limited 2013 Science and technology of nuclear installations Vol.2013 No.-
<P>Pyroprocessing technology has been actively developed at Korea Atomic Energy Research Institute (KAERI) to meet the necessity of addressing spent fuel management issue. This technology has advantages over aqueous process such as less proliferation risk, treatment of spent fuel with relatively high heat and radioactivity, and compact equipments. This paper describes the pyroprocessing technology development at KAERI from head-end process to waste treatment. The unit process with various scales has been tested to produce the design data associated with scale-up. Pyroprocess integrated inactive demonstration facility (PRIDE) was constructed at KAERI and it began test operation in 2012. The purpose of PRIDE is to test the process regarding unit process performance, remote operation of equipments, integration of unit processes, scale-up of process, process monitoring, argon environment system operation, and safeguards-related activities. The test of PRIDE will be promising for further pyroprocessing technology development.</P>
Biochemical Properties of Human Organ - Specific Acid Phosphatase Isoenzymes
Hansoo Lee 생화학분자생물학회 1994 BMB Reports Vol.27 No.3
Four acid phosphatases (AcP) were newly purified to homogeneity from human lung, spleen, kidney, and bladder using affinity chromatography on L(+)-tartrate, an inhibitor of AcP. The biochemical properties of these 4 phosphatases were compared with the properties of phosphatase isolated from human prostate. All had a similar molecular weight of approximately 100 kDa, and exhibited maximum enzymic activity at pH 5.5 to 6.0. These acid phosphatases from the human lung, spleen, kidney, and bladder had similar substrate affinities toward several phosphomonoester substrates, and exhibited highest reactivities toward p-nitrophenyl phosphate, among the substrates examined. The AcP of the prostate had highest affinity toward α-naphthyl phosphate. Phosphotyrosine phosphatase activity on ^(32)P-Tyr-labelled phosphopeptide substrates was demonstrated primarily by the AcP of the prostate. Although all AcP isoenzymes were inhibited to a similar extent by L(+)-tartrate, Fe^(3+), and fluoride, the AcP of the prostate was more sensifive to inhibition by Ca^(2+), Ba^(2+), La^(2+), and ethanol than the other AcP isoenzymes. The amino acid compositions of lung, spleen, kidney, and bladder AcP`s were almost identical, but were different from the amino acid composition of prostatic AcP. These results suggest that the acid phosphatases of the human lung, spleen, kidney, and bladder are products of the same gene, and are protein molecules distinct from the acid phosphatase of the human prostate.